{"url_path":"/sec/elox/8-k/2026-06-01/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-249692-index.html","accession_number":"0001193125-26-249692","cik":"0001035354","ticker":"ELOX","issuer_name":"Eloxx Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-249692-index.html","primary_entity_key":"0001035354","primary_entity_name":"Eloxx Pharmaceuticals, Inc."},"word_count":163,"has_tables":true,"body_markdown":"Item 3.02.\n\nUnregistered Sales of Equity Securities.\n\nOn August 20, 2025, the Company entered into that certain Securities Purchase Agreement with the investors party thereto (as amended, the “Purchase Agreement”), pursuant to which the Company issued and sold prefunded warrants to purchase an aggregate of 54,076,677 shares of common stock, par value $0.01 per share (the “Common Stock”), with an exercise price of $0.01 per share. On April 27, 2026, certain of the investors exercised pre-funded warrants to purchase an aggregate of 2,500,000 shares of Common Stock (the “Prefunded Warrant Exercise”). On May 27, 2026, such investors exchanged 2,500,000 shares of Common Stock issued in the Prefunded Warrant Exercise for prefunded warrants to purchase an equal number of shares of Common Stock, at an exercise price of $0.01 per share. These transactions were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were conducted pursuant to the exemption provided in Sections 4(a)(2) and/or 3(a)(9) under the Securities Act."}